Reviva Pharmaceuticals Secures $9M for Clinical Development

Reviva Pharmaceuticals, Inc. (NASDAQ: RVPH) has announced it has successfully raised $9,000,000 in a funding round from investors. The Santa Clara, California-based company, a publicly traded late-stage clinical development pharmaceutical firm, focuses on developing internally discovered innovative therapies. This capital infusion is intended to advance its portfolio of next-generation treatments designed to address unmet medical needs across central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva is distinguished by its chemical genomic driven approaches and proprietary technologies, aiming for speed without sacrificing quality in its product development. The company possesses a robust patent portfolio and multiple promising products in various stages of development. The newly secured funds are significant as they will support the continued advancement of its pipeline, particularly its lead product, RP5063. This multimodal neuromodulator has successfully completed global Phase 2 clinical trials, demonstrating a superior efficacy and safety profile for schizophrenia and schizoaffective disorder. Following a successful End of Phase 2 (EOP2) meeting with the U.S. FDA, Reviva is now preparing to initiate global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The $9,000,000 investment will be crucial in supporting these upcoming large-scale clinical trials and other operational requirements. Furthermore, Reviva plans to broaden the development scope of RP5063 to encompass bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD), and autism spectrum disorders. The leadership team, comprising highly experienced professionals from the pharmaceutical industry, brings a demonstrated track record in drug development and global market entry. With this new capital, Reviva Pharmaceuticals is positioned to accelerate its clinical programs and further solidify its commitment to bringing innovative therapies to patients suffering from complex conditions. The company anticipates this funding will enable significant progress in its mission to address critical unmet medical needs.